Biotech Binary Catalysts Cluster 2026-2027: OCU410 Shows 31% Lesion Reduction, SIL204 Enters Phase 2/3 for Pancreatic Cancer
Clinical-stage biotech companies are advancing ophthalmology and oncology programs toward key regulatory milestones in 2026-2027. Ocugen's OCU410 gene therapy demonstrated 31% lesion reduction in geographic atrophy, while Silexion's KRAS-targeted SIL204 received approval to begin Phase 2/3 trials in pancreatic cancer.
Salvado•